Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15709294 | 1.00 | MEN1 (0.58) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL15730819 | 0.92 | MEN1 (0.50) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL20869707 | 0.82 | ALDH1A1 (0.50) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL3215060 | 0.80 | ALDH1A1 (0.61) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL1042441 | 0.79 | ALDH1A1 (0.58) | MEN1KMT2AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3197983 | 0.77 | ALDH1A1 (0.57) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL28958487 | 0.76 | MAPT (0.48) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL20873634 | 0.75 | KMT2A (0.55) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL28880810 | 0.75 | HPGD (0.61) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL6260274 | 0.75 | ALDH1A1 (0.55) | MEN1KMT2AKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11975032-B2 | Medicament for liver regeneration and for treatment of liver failure | MEDIZINISCHE HOCHSCHULE HANNOVER (DE) | 2024-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11975032-B2 | Medicament for liver regeneration and for treatment of liver failure | PYGL, HNF4A, ATF1 | MEN1 3939/4885KMT2A 2105/4885KDM4E 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.